Tablet variations of the weight problems medicine now taken solely as injections are on the way in which. We take a look at the science behind the capsules and in the event that they is likely to be extra inexpensive and accessible than the pictures.
AYESHA RASCOE, HOST:
Medication like Wegovy and Ozempic have develop into more and more widespread choices for tens of millions of people that need to attain a more healthy weight. However the medicine, taken as weekly injections, aren’t for everyone or each pockets. That is why experimental capsules that might do the identical factor are drawing a lot consideration. A Wegovy-style capsule is anticipated to win approval from the Meals and Drug Administration by the tip of the yr. NPR prescribed drugs correspondent Sydney Lupkin is right here to speak with us about that risk. Good to have you ever right here, Sydney.
SYDNEY LUPKIN, BYLINE: Thanks for having me.
RASCOE: Why hasn’t there been a capsule model of those medicine till now? I imply, it looks like one thing lots of people would need.
LUPKIN: Yeah. I imply, it is a good query. And there kind of is. It is referred to as Rybelsus, but it surely’s solely accredited for Sort 2 diabetes. It is made by Novo Nordisk, which is identical firm that makes Ozempic for Sort 2 diabetes and Wegovy for weight problems. However it’s a decrease dose of the lively ingredient these injectable medicine share – semaglutide. The brand new capsule could be the next dose geared toward sufferers with weight problems, and research present its efficacy is fairly near Wegovy’s. Tracy Zvenyach is the director of coverage technique and alliances on the nonprofit Weight problems Motion Coalition. She says extra choices could be an enormous deal.
TRACY ZVENYACH: The affected person neighborhood within the weight problems area has been residing with out – gone with out remedy for therefore lengthy. So new improvements, new therapies to deal with this persistent illness – all are welcome. All are thrilling.
LUPKIN: She says lots of sufferers are hopeful concerning the new capsules, notably in the event that they’ve had a tough time accessing the injections for one cause or one other.
RASCOE: OK. So how would this new capsule work? Is it the identical because the injectable variations?
LUPKIN: So semaglutide, that lively ingredient, will get damaged down fairly shortly within the abdomen – too shortly to truly get absorbed and do its job. That is why it is principally been an injectable. So Novo Nordisk added one thing to it to repair that. It is a chemical with a protracted title, however the abbreviation is S-N-A-C – SNAC. Andrea Traina, one in all Novo Nordisk’s weight problems administrators, defined the way it works.
ANDREA TRAINA: If you consider dropping an Alka-Seltzer pill in a glass of water, that instant fizzy response that happens – that’s what occurs in your abdomen as quickly as this pill hits the bottom of your abdomen, hits that abdomen wall.
LUPKIN: It creates this fizzy surroundings simply across the capsule, blocking the abdomen acids from breaking it down too shortly and giving it sufficient time to get absorbed into the bloodstream. It takes about half-hour. So the capsule must be taken on an empty abdomen, and you’ll’t eat or take different drugs till it is absorbed.
RASCOE: OK. It looks like that may flip no less than some individuals off. What have you ever heard from sufferers?
LUPKIN: Yeah. Properly, there are different widespread medicine that individuals already take that must be taken the identical method, so it is not a deal breaker for everybody. However not everyone seems to be . If the injections are already working nicely for them, this could be a every day capsule. The injections are weekly. However the huge hope from sufferers is that this capsule can be cheaper and get higher insurance coverage protection than the injections. One individual advised me they only hope it is cheaper than their mortgage.
Dr. Richard Siegel is an endocrinologist at Tufts Medical Middle.
RICHARD SIEGEL: However one of many huge issues with all the medicines on this area has been the fee, and may we equitably get these medicines to the hundreds – you already know, tens of millions, actually – of people that may profit from them?
LUPKIN: He says three-quarters of the messages he will get from sufferers are about these medicine, and lots of them are coping with renewals and insurance coverage firms. His workplace is staffed to deal with that, however not each physician’s workplace is. When some individuals lose insurance coverage protection, they’ll afford a couple of hundred {dollars} a month to purchase instantly from the drug producers. However lots of people cannot, even with latest firm reductions that make it as little as $200 a month in some instances.
RASCOE: So do you assume the capsules really can be cheaper?
LUPKIN: So I do not know for certain, however capsules sometimes are cheaper to make than medicine given by injection. The injector pens also can add to the fee. As for Novo Nordisk, it hasn’t introduced its sticker value but. Nevertheless, as a part of a cope with the Trump administration, it stated that for sufferers not utilizing their insurance coverage, they’d supply it for $149 a month. That is a less expensive direct-to-consumer value than for injectables, so it may very well be an encouraging signal. The corporate says entry is a matter that it is engaged on with different components of the drug provide chain.
RASCOE: That was NPR prescribed drugs correspondent Sydney Lupkin. Thanks a lot, Sydney.
LUPKIN: You guess.
Copyright © 2025 NPR. All rights reserved. Go to our web site phrases of use and permissions pages at www.npr.org for additional data.
Accuracy and availability of NPR transcripts might fluctuate. Transcript textual content could also be revised to appropriate errors or match updates to audio. Audio on npr.org could also be edited after its unique broadcast or publication. The authoritative report of NPR’s programming is the audio report.
